Attralus

Focus: Attralus is a biotechnology company focused on developing treatments for amyloidosis, a rare protein-folding disease with significant unmet medical need. The company operates from Naples, FL with a specialized focus on this niche but growing therapeutic area.

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Attralus

AI assessmentNot Hiring

No open roles listed right now. Follow Attralus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.

Systemic Amyloidosis

Phase 1

Clinical Trials (1)

NCT05951816A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Phase 1

Help build intelligence for Attralus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in amyloidosis, a high-priority therapeutic area with recent FDA approvals and growing clinical interest
Early-stage biotech environment offers potential for rapid career progression and direct impact on drug development decisions
Specialized focus on rare disease allows for deep scientific expertise and niche market leadership positioning

Watch Out For

Company stage and funding data are not publicly available, creating uncertainty around financial stability and runway
Zero active job openings at time of analysis suggests minimal near-term hiring or potential organizational challenges
No disclosed clinical trial data, publications, or recent news makes it difficult to assess scientific credibility or momentum

Generated by Claude from Attralus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AT-02

Amyloidosis; Systemic

Phase 1

Clinical Trials (1)

NCT05521022Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Phase 1

124I-AT03

Amyloidosis; Systemic

Phase 1

Clinical Trials (1)

NCT05201911A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

Phase 1